{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:11:49Z","timestamp":1790773909286,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":4280,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1177\/1087057110373392","type":"journal-article","created":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T22:12:22Z","timestamp":1277503942000},"page":"806-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Composite Primary Neuronal High-Content Screening Assay for Huntington\u2019s Disease Incorporating Non-Cell-Autonomous Interactions"],"prefix":"10.1016","volume":"15","author":[{"given":"Linda S.","family":"Kaltenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mclean","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Kanju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn M.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Turmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"O. Joseph","family":"Trask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1177\/1087057110373392_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1177\/1087057110373392_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"a novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1177\/1087057110373392_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1146\/annurev.neuro.29.051605.113042","article-title":"Trinucleotide repeat disorders","volume":"30","author":"Orr","year":"2007","journal-title":"Annu Rev Neurosci"},{"key":"10.1177\/1087057110373392_bib4","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1177\/1087057110373392_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1177\/1087057110373392_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0092-8674(00)80514-0","article-title":"Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo","volume":"90","author":"Scherzinger","year":"1997","journal-title":"Cell"},{"key":"10.1177\/1087057110373392_bib7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington\u2019s disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1177\/1087057110373392_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pneurobio.2006.11.004","article-title":"Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington\u2019s disease","volume":"83","author":"Truant","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1177\/1087057110373392_bib9","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1074\/jbc.R800065200","article-title":"Animal models of polyglutamine diseases and therapeutic approaches","volume":"284","author":"Marsh","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1177\/1087057110373392_bib10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.drudis.2009.02.006","article-title":"Small molecule drug discovery for Huntington\u2019s disease","volume":"14","author":"Fecke","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1177\/1087057110373392_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/138620708783877753","article-title":"High throughput screening for neurodegeneration and complex disease phenotypes","volume":"11","author":"Varma","year":"2008","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1177\/1087057110373392_bib12","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1073\/pnas.2628045100","article-title":"A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila","volume":"100","author":"Apostol","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1177\/1087057110373392_bib13","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/hmg\/ddl135","article-title":"Biologically active molecules that reduce polyglutamine aggregation and toxicity","volume":"15","author":"Desai","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1177\/1087057110373392_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-6-1","article-title":"Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation","volume":"6","author":"Wang","year":"2005","journal-title":"BMC Neurosci"},{"key":"10.1177\/1087057110373392_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0076-6879(06)13016-5","article-title":"Screening for modulators of aggregation with a microplate elongation assay","volume":"413","author":"Berthelier","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1177\/1087057110373392_bib16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1177\/1087057110373392_bib17","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1111\/j.1742-4658.2008.06561.x","article-title":"Huntington\u2019s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases","volume":"275","author":"Truant","year":"2008","journal-title":"FEBS J"},{"key":"10.1177\/1087057110373392_bib18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nbd.2004.04.001","article-title":"A cell-based screen for drugs to treat Huntington\u2019s disease","volume":"16","author":"Aiken","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1177\/1087057110373392_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/hmg\/ddh045","article-title":"A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor","volume":"13","author":"Piccioni","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1177\/1087057110373392_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nchembio852","article-title":"Selective inhibitors of death in mutant huntingtin cells","volume":"3","author":"Varma","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1177\/1087057110373392_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.nbd.2005.03.026","article-title":"Compounds blocking mutant huntingtin toxicity identified using a Huntington\u2019s disease neuronal cell model","volume":"20","author":"Wang","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1177\/1087057110373392_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington\u2019s disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1177\/1087057110373392_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","article-title":"The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies","volume":"2","author":"Li","year":"2005","journal-title":"NeuroRx"},{"key":"10.1177\/1087057110373392_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1326-2-8","article-title":"Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington\u2019s disease","volume":"2","author":"Gu","year":"2007","journal-title":"Mol Neurodegener"},{"key":"10.1177\/1087057110373392_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neuron.2005.03.025","article-title":"Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice","volume":"46","author":"Gu","year":"2005","journal-title":"Neuron"},{"key":"10.1177\/1087057110373392_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.58.5.695","article-title":"Regional and progressive thinning of the cortical ribbon in Huntington\u2019s disease","volume":"58","author":"Rosas","year":"2002","journal-title":"Neurology"},{"key":"10.1177\/1087057110373392_bib27","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.20979","article-title":"Diffusion tensor imaging in presymptomatic and early Huntington\u2019s disease: selective white matter pathology and its relationship to clinical measures","volume":"21","author":"Rosas","year":"2006","journal-title":"Mov Disord"},{"key":"10.1177\/1087057110373392_bib28","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1046\/j.1460-9568.2003.02696.x","article-title":"Formation of dendritic spines in cultured striatal neurons depends on excitatory afferent activity","volume":"17","author":"Segal","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1177\/1087057110373392_bib29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.conb.2009.10.002","article-title":"High-content screening of primary neurons: ready for prime time","volume":"19","author":"Daub","year":"2009","journal-title":"Curr Opin Neurobiol"},{"key":"10.1177\/1087057110373392_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00656997","article-title":"Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches","volume":"391","author":"Hamill","year":"1981","journal-title":"Pflugers Arch"},{"key":"10.1177\/1087057110373392_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"10.1177\/1087057110373392_bib32","series-title":"The Synaptic Organization of the Brain","first-page":"361","article-title":"Basal ganglia","author":"Wilson","year":"2004"},{"key":"10.1177\/1087057110373392_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","article-title":"Role of brain-derived neurotrophic factor in Huntington\u2019s disease","volume":"81","author":"Zuccato","year":"2007","journal-title":"Prog Neurobiol"},{"key":"10.1177\/1087057110373392_bib34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0896-6273(03)00697-4","article-title":"A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor","volume":"40","author":"Pollitt","year":"2003","journal-title":"Neuron"},{"key":"10.1177\/1087057110373392_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nbd.2009.06.011","article-title":"Y-27632 improves rotarod performance and reduces huntingtin levels in R6\/2 mice","volume":"36","author":"Li","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1177\/1087057110373392_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.tips.2007.04.006","article-title":"Development of Rho-kinase inhibitors for cardiovascular medicine","volume":"28","author":"Shimokawa","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1177\/1087057110373392_bib37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/TCRM.S2907","article-title":"The therapeutic effects of Rho-ROCK inhibitors on CNS disorders","volume":"4","author":"Kubo","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1177\/1087057110373392_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/bj3510095","article-title":"Specificity and mechanism of action of some commonly used protein kinase inhibitors","volume":"351","author":"Davies","year":"2000","journal-title":"Biochem J"},{"key":"10.1177\/1087057110373392_bib39","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.febslet.2008.04.009","article-title":"ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation","volume":"582","author":"Shao","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1177\/1087057110373392_bib40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.nbd.2008.02.010","article-title":"Beneficial effects of rolipram in the R6\/2 mouse model of Huntington\u2019s disease","volume":"30","author":"DeMarch","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1177\/1087057110373392_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nbd.2006.09.006","article-title":"Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity","volume":"25","author":"DeMarch","year":"2007","journal-title":"Neurobiol Dis"},{"key":"10.1177\/1087057110373392_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.expneurol.2007.02.010","article-title":"Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV","volume":"211","author":"Yang","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1177\/1087057110373392_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/hmg\/ddg046","article-title":"Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice","volume":"12","author":"Gines","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1177\/1087057110373392_bib44","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2174\/138161208784480117","article-title":"A critical evaluation of adenosine A2A receptors as potentially \u201cdruggable\u201d targets in Huntington\u2019s disease","volume":"14","author":"Popoli","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1177\/1087057110373392_bib45","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1523\/JNEUROSCI.2675-04.2004","article-title":"Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity","volume":"24","author":"Khoshnan","year":"2004","journal-title":"J Neurosci"},{"key":"10.1177\/1087057110373392_bib46","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.bmcl.2004.03.058","article-title":"Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors","volume":"14","author":"Baxter","year":"2004","journal-title":"Bioorg Med Chem Lett"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1087057110373392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1087057110373392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555222079527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555222079527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1087057110373392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:36:17Z","timestamp":1762860977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555222079527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S2472555222079527"],"URL":"https:\/\/doi.org\/10.1177\/1087057110373392","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composite Primary Neuronal High-Content Screening Assay for Huntington\u2019s Disease Incorporating Non-Cell-Autonomous Interactions","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1177\/1087057110373392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Society for Laboratory Automation and Screening. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}